Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/01/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: August 1, 2018 - August 31, 2018

(Unaudited)

 

$USD ‘000s

Debtor

  

Bank

   Last Four Digits
Account No.
    

Account Description

   Beginning
Balance
8/1/2018
     Ending
Balance
8/31/2018
 

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      6813      General checking    $ —         $ —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      1180      Zero-balance lockbox(2)      —          —    

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      3036      Sweep account      36,981        37,483  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      7307      Utility adequate assurance      10        10  

Orexigen Therapeutics, Inc.

   Silicon Valley Bank      5177      Collateral      100        100  
           

 

 

    

 

 

 

Total Bank Account Balances

            $ 37,091      $ 37,593  
           

 

 

    

 

 

 

Notes:

 

(1)

The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-1a) represent book balances while MOR-1b represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.

(2)

Account was closed in September 2018.